An Early Look at EHA 2026: 10 Key Studies Heading to Stockholm
A sneak peek at the heme-onc abstracts at EHA 2026: CLL triplets, frontline menin inhibition, earlier myeloma bispecifics, and post‑JAK myelofibrosis combos poised to shift care.
The 2026 European Hematology Association (EHA) Congress arrives at a time when several of hematologic oncology’s most important treatment paradigms are being challenged—fixed-duration regimens are redefining expectations in chronic lymphocytic leukemia (CLL), bispecific antibodies are moving into earlier stages of multiple myeloma, and a new generation of targeted therapies is attempting to overcome resistance in diseases ranging from acute myeloid leukemia (AML) to myelofibrosis. Below, we’ve shortlisted some of the abstracts most likely to generate discussion this year in Stockholm.